Several studies assessing the efficacy of AAS in the treatment of acquired and constitutional aplastic anemia have been done. Some studies resulted in a sustained hematological response and others, in a few cases, induced complete remission. In studies the effect on short term survival among patients randomized to receive antilymphocyte globulin and methylprednisolone, with or without oxymetholone, revealed no difference with the addition of an AAS. There are, however, limited case reports where patients with acquired aplastic anemia were placed on continuous androgen treatment to maintain adequate blood counts. Therefore, the use of AAS for the treatment of acquired aplastic anemia is still under discussion. Oxymetholone has been shown to have an erythropoietic and myelopoietic effect. There have been studies in which oxymetholone was successfully used in a variety of hematologic disorders including sickle cell anemia, hairy cell leukemia, benzene-induced bone marrow damage, aplastic anemia complicating systemic lupus erythematosus, cyclic neutropenia, refractory anemia type 1 FAB (French-American-British classification), and bone marrow failure associated with clonal disorders.